Oral anticoagulation following bioprosthetic SAVR in patients with atrial fibrillation: what's the current status of NOACs?

Interact Cardiovasc Thorac Surg. 2022 Jun 15;35(1):ivac112. doi: 10.1093/icvts/ivac112.

Authors

Milan Milojevic¹, Aleksandar Nikolic², Slobodan Micovic¹, Anders Jeppsson^{3

4}

Affiliations

¹ Department of Cardiac Surgery and Cardiovascular Research, Dedinje Cardiovascular Institute, Belgrade, Serbia.
² Department of Cardiac Surgery, Acibadem-Sistina Hospital, Skopje, North Macedonia.
³ Department of Molecular and Clinical Medicine, Sahlgrenska Academy, Gothenburg University, Gothenburg, Sweden.
⁴ Department of Cardiothoracic Surgery, Sahlgrenska University Hospital, Gothenburg, Sweden.

No abstract available

Keywords: Bioprosthetic heart valves; Non-vitamin K antagonist oral anticoagulant; Oral anticoagulation; Surgical aortic valve replacement.

Publication types

Comment

MeSH terms

Administration, Oral
Anticoagulants / adverse effects
Atrial Fibrillation* / diagnosis
Atrial Fibrillation* / drug therapy
Heart Valve Prosthesis*
Humans
Stroke* / etiology
Stroke* / prevention & control
Thromboembolism*

Substances

Anticoagulants